Medical Device Weekly Insights (April 13–19, 2026): Innovations, Approvals, and Strategic Funding Rounds

Recently, the headquarters of China's leading flexible rehabilitation robot company in brain-computer interface, Conmind, has commenced operations in Liangxi District. This marks the establishment of an integrated "research and development – manufacturing – service" system, injecting momentum into the intelligent rehabilitation sector in the Yangtze River Delta. Specializing in hand-function flexible rehabilitation robots, Conmind collaborates with top-tier teams. Its products have been approved for a Class III medical device registration certificate for brain-computer interfaces and have deployed hundreds of devices across various regions. They are included in Wuxi City’s community rental service directory for rehabilitation aids and have simultaneously launched "Internet + Home Rehabilitation" services. On the same day, Conmind released its Brain-Computer Interface Cloud Rehabilitation Platform to address the challenge of “loss of management upon discharge,” building a “digital bridge” that extends resources from tertiary hospitals to households. Additionally, Liangxi District organized a closed-door symposium where government, enterprises, research institutions, and investors engaged in in-depth discussions, reaching consensus to accelerate the industrial clustering of brain-computer interface technologies.

Recently, the Third-Party Real-Scene Medical Training and Achievement Transformation Platform, Shuimu Jingzhi, opened in Beijing. The platform collaborates with multiple medical enterprises to address the standardization challenges of grassroots endoscopic techniques. For instance, Shuyou Medical empowers practical training with innovative instruments, Bangyun Medical enhances surgical efficiency with knotless barbed sutures, and Huanuo Kang provides high-end equipment to strengthen hardware foundations. The real-scene training model integrates academic standards, practical scenarios, and industrial resources, establishing a standardized growth platform for grassroots surgeons and promoting the homogenized development of surgical diagnostic techniques. This platform represents a critical innovation practice in the field of medical technology achievement transformation, completing the closed loop of medical innovation achievement transformation. It is reported that the platform will next collaborate with more industry partners to upgrade the training system, promote standardized procedures and innovative instruments to extend into county-level areas, and cultivate grassroots surgical talents.

Recently, Wuhan United Imaging Intelligence Medical Technology Co., Ltd., a company based in Optics Valley, successfully developed a self-innovated endoscopic surgical robot with imaging fusion capabilities. The robot has been applied clinically across multiple departments in several Class A tertiary hospitals in China, including hepatobiliary, urology, gastrointestinal, gynecology, and thoracic surgery, demonstrating excellent results. It is set to be officially launched within the year. This achievement marks a significant breakthrough for United Imaging in the field of high-end medical equipment. Additionally, United Imaging has made extensive progress under this system, successfully developing a range of products including CT real-time image-guided interventional surgical robots and the Magic Cube Hybrid Operating Room, showcasing its strong innovation capabilities and deep technological expertise in the medical technology sector.

Recently, at the Brain-Computer Interface Clinical Application and Transformation Conference in China, the Fengtai-Tiantan Major Brain-Computer Interface Project was announced. Fengtai District and Beijing Tiantan Hospital will jointly build a brain-computer interface innovation industrial park, planning 500,000 square meters of industrial space, and establish a Brain-Computer Interface Clinical Research and Transformation Alliance. The focus will be on building four research centers: the Brain Research Center, the Brain Computing Power Center, the Brain Health Center, and the Brain Rehabilitation Center, which will respectively focus on key technology R&D breakthroughs, providing computing power support, deepening full-cycle brain disease management, and constructing a new paradigm for brain-controlled active rehabilitation. In addition, the two parties will also build a large brain health model and launch an "AI Brain Health Doctor." Fengtai District will collaborate with social capital to establish an industrial fund, construct a "1+N" fund matrix, promote enterprises and R&D centers to move into the park, focus on overcoming cutting-edge technological challenges, and accelerate the clinical application and industrialization process of brain-computer interface technology.

Recently, the "Concept Verification Center" of the NeuroMedical Innovation and Translation Alliance (CNIT) has settled in Tongqiao Medical, located in Zhuhai High-Tech Zone, marking the establishment of a national-level industry-university-research collaborative innovation platform in China's neurovascular intervention field. This strengthens Zhuhai High-Tech Zone's "clinical-research-industry" collaborative innovation system. The center's establishment is a recognition of Tongqiao Medical's independent innovation capabilities, which will shorten the transformation cycle of neurovascular intervention devices and accelerate the market entry of innovative achievements. Chairman Zhao Zhong of Tongqiao Medical hopes to deepen cooperation and promote the transformation of results through this opportunity; General Manager Li Zheng showcased the company’s innovative development process and core technology advantages, with several technologies filling domestic gaps. On the same day, the fourth phase project selection activity of CNIT Innovation Academy was also held, where experts discussed key industry issues.

On April 10, 2026, Revvity officially signed a strategic cooperation agreement with Lead Health Technology. Liu Jiang, Vice President of Revvity, and Zhang Feng, CEO of Lead Health, represented the signing, with both core teams in attendance. This collaboration focuses on solution innovation and localization exploration, building an end-to-end innovative ecosystem around the cell industry chain, and enhancing supply chain stability and product standardization. During the signing ceremony, both parties held discussions on the local layout and international high-quality development of life science instruments. Zhang Feng stated that Lead Health would leverage Revvity’s global resources to optimize the production transfer process and address industry pain points. Liu Jiang noted that Revvity's technology complements Lead Health’s local innovation strengths, which will advance the localization of products. This partnership achieves resource complementarity and mutual benefit, injecting momentum into the high-end and international upgrade of China’s life science instrument and equipment industry, and promoting domestic scientific and technological achievements to reach the global stage.

On April 12, the Xirun Medical Headquarters Base project began operations in Liangxi District, Wuxi, marking the establishment of an integrated "R&D-Manufacturing-Service" system and entering a new stage of development. This also injects momentum into Liangxi District's efforts to build a smart rehabilitation hub. Xirun Medical focuses on the field of hand function flexible rehabilitation robots and collaborates with top-tier teams. Their products can help high-level paraplegic patients control their fingers through "thought," with invasive brain-computer interface rehabilitation products completing dozens of clinical trials and obtaining the world's first Class III medical device registration certificate. The company has simultaneously launched "Internet + Home Rehabilitation" services and released a brain-computer interface cloud rehabilitation platform to solve the problem of "loss of management upon discharge" and reduce patient costs. In the future, the company will deepen cooperation with its Liangxi headquarters as the base, promoting the extension of rehabilitation services. The establishment of Xirun Medical represents the achievement of Liangxi District's efforts to develop the brain-computer interface industry ecosystem. An ecosystem enterprise closed-door symposium was also held on the day of production commencement.

Recently, B. Braun Medical from Germany announced the groundbreaking of the third phase project of its Suzhou surgical instruments factory, with a total investment of nearly 100 million yuan, scheduled to commence operations in 2027. B. Braun Medical Group has a long history and ranks 15th among the top 100 global medical device companies, with businesses covering multiple core areas of healthcare. This increased investment in China aims to bring forward the global core surgical instrument production capacity, utilizing local manufacturing to respond to centralized procurement, shorten delivery cycles, reduce costs, and maintain high-end market barriers. The third phase project focuses on localized production of high-precision basic surgical instruments, with an annual production capacity of 3 million units upon reaching full operation, adding over 100 million yuan in output value. Additionally, the MES system will be used to achieve full-chain digitalization of production. Currently, as China's medical device manufacturing undergoes transformation, B. Braun’s practices provide the industry with a replicable model for the localization of high-end foreign devices, deeply integrating German industrial standards with China’s supply chain to enhance the voice of "Made in China."

Recently, the State Council Information Office held a regular briefing on State Council policies to introduce the relevant situation of the "Several Measures on Accelerating the Construction of a Hierarchical Diagnosis and Treatment System." First, it encourages grassroots organizations to make good use of pricing policies to provide appropriate services. Grassroots organizations are guided to effectively implement price project policies, combining them with project establishment guidelines, encouraging the use of home visit fees, hospice care fees, family bed setup fees, internet re-examination fees, Traditional Chinese Medicine rehabilitation services, and other projects; optimizing price management in primary healthcare institutions and implementing general treatment fee policies. Second, it supports large hospitals in applying new clinical services and technologies. Third, it continuously optimizes the structure of medical service prices. Since 2021, all provinces in China have established a dynamic adjustment mechanism for medical service prices. Each region conducts price adjustment evaluations annually, and regions meeting the adjustment criteria can proceed with price adjustments. The adjustment of medical service prices reflects "both increases and decreases," with prices for inspection items mainly based on equipment consumption, such as CT and MRI, being reduced.

Recently, "The Guiding Opinions on Promoting the High-Quality Development of the Biomedical Industry in Zhejiang Province (Draft for Soliciting Opinions)" was opened for public comments. It mentioned supporting the research and development of cutting-edge technologies and products. Driven by clinical needs, efforts will be accelerated to lay out frontier areas such as cell and gene therapy, novel antibody drugs, new small molecule drugs, nucleic acid drugs, radiopharmaceuticals, modern Chinese medicine, medical artificial intelligence, and high-end medical devices, while formulating key R&D lists for innovative drugs and innovative medical devices. Systematic implementation of applied basic research projects in the biomedical field and major provincial science and technology special projects will be carried out. Support will be given to the construction of biopharmaceutical intellectual property operation centers, deepening patent navigation analysis, and providing rapid pre-examination services for high-value patents.

Recently, the Hunan Provincial Medical Security Bureau announced that the National Healthcare Security Administration's "Guidelines for the Establishment of Medical Service Price Items for Surgical and Therapeutic Auxiliary Operations (Trial)" has been implemented in Hunan. Previously, surgical robot fees were charged "based on equipment usage," with unclear categories, increasing the burden on patients and making it difficult for medical insurance to intervene. The new guidelines set prices based on the level of the robot’s involvement and clinical value in surgery—the higher the involvement, the higher the charge coefficient—and also introduce a "remote surgical assistance operation fee." Hunan has responded to the new regulations by categorizing charges into four tiers: navigation-type operations are charged at 50% of the main surgery price, capped at 3,600 yuan; participation execution-type operations are charged at 150%, capped at 12,000 yuan with a minimum of 5,000 yuan; precision execution-type operations are charged at 300%, capped at 26,000 yuan with a minimum of 16,000 yuan; remote surgery-type operations are charged at 500%, capped at 37,000 yuan.

On April 13, the National Center for ADR Monitoring of Medicinal Products released the "Good Vigilance Practice for Medical Devices (Trial) (Revised Version)" to standardize post-market vigilance activities for medical devices. The GVP comprises 8 chapters and 33 articles, applicable to medical device registrants, record-filers, and domestic responsible persons for imported medical devices in China. It requires them to establish a medical device vigilance system, formulate vigilance plans commensurate with product risks, and monitor, identify, assess, and control adverse events related to medical devices, reducing uncertainties in harm and risk occurrence to ensure the safety of relevant personnel. The vigilance system must be integrated into the quality management system, focusing on eight key aspects such as organizational structure setup and management system formulation. The vigilance plan is an important document, covering product scope, vigilance objectives, and other items. Additionally, the GVP specifies content related to vigilance data collection and risk control. Drug regulatory authorities in 17 provinces (regions, municipalities) including Beijing and Hebei will organize the trial implementation.